CZ74797A3 - Composition for specific intracellular introduction of a chemical agent and method of such introduction - Google Patents

Composition for specific intracellular introduction of a chemical agent and method of such introduction Download PDF

Info

Publication number
CZ74797A3
CZ74797A3 CZ97747A CZ74797A CZ74797A3 CZ 74797 A3 CZ74797 A3 CZ 74797A3 CZ 97747 A CZ97747 A CZ 97747A CZ 74797 A CZ74797 A CZ 74797A CZ 74797 A3 CZ74797 A3 CZ 74797A3
Authority
CZ
Czechia
Prior art keywords
seq
receptor
ligand
composition
cells
Prior art date
Application number
CZ97747A
Other languages
Czech (cs)
English (en)
Inventor
Ramesh K Prakash
Original Assignee
Theratech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech filed Critical Theratech
Publication of CZ74797A3 publication Critical patent/CZ74797A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ97747A 1994-09-13 1995-09-12 Composition for specific intracellular introduction of a chemical agent and method of such introduction CZ74797A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
PCT/US1995/011515 WO1996008263A1 (fr) 1994-09-13 1995-09-12 Administration intracellulaire d'agents chimiques a un type specifique de cellules

Publications (1)

Publication Number Publication Date
CZ74797A3 true CZ74797A3 (en) 1997-08-13

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ97747A CZ74797A3 (en) 1994-09-13 1995-09-12 Composition for specific intracellular introduction of a chemical agent and method of such introduction

Country Status (13)

Country Link
EP (1) EP0781139A1 (fr)
JP (1) JPH10505835A (fr)
KR (1) KR970705404A (fr)
CN (1) CN1157570A (fr)
AU (1) AU697469B2 (fr)
BR (1) BR9508951A (fr)
CA (1) CA2198361A1 (fr)
CZ (1) CZ74797A3 (fr)
HU (1) HUT77263A (fr)
MX (1) MX9701860A (fr)
PL (1) PL319100A1 (fr)
WO (1) WO1996008263A1 (fr)
ZA (1) ZA957688B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ, インコーポレイテッド インターロイキン−2レセプターに標的化された結合体
EP1166775B1 (fr) * 1997-11-19 2010-03-03 Georgetown University Apport ciblé de gènes dans un liposome vecteur
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CN110139655A (zh) 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Also Published As

Publication number Publication date
BR9508951A (pt) 1999-04-06
KR970705404A (ko) 1997-10-09
WO1996008263A1 (fr) 1996-03-21
CA2198361A1 (fr) 1996-03-21
PL319100A1 (en) 1997-07-21
AU697469B2 (en) 1998-10-08
AU3550795A (en) 1996-03-29
CN1157570A (zh) 1997-08-20
JPH10505835A (ja) 1998-06-09
EP0781139A1 (fr) 1997-07-02
HUT77263A (hu) 1998-03-02
MX9701860A (es) 1997-06-28
ZA957688B (en) 1996-05-13

Similar Documents

Publication Publication Date Title
AU695196B2 (en) Nucleic acid transfer system
CA2190494C (fr) Composition de support d'immunogene de polypetide d'heterodimere et son procede d'utilisation
US5428143A (en) Cytotoxic agent against specific virus infection
KR20030025901A (ko) 염증성 반응 억제용 세포 투과성 펩티드 및 사용방법
AU1193999A (en) J-chain and analogues as epithelial cell targeting conjugates
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
WO2013036973A2 (fr) Procédés et compositions de régulation d'un assemblage de protéines virales
CA2406352A1 (fr) Conjugues de peptides utilises pour l'apport de medicament
WO1996008274A2 (fr) Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
JP2001511122A (ja) 新規な上皮組織標的化薬剤
CZ74797A3 (en) Composition for specific intracellular introduction of a chemical agent and method of such introduction
JP2510846B2 (ja) PE40Abを含有するタンパク質抗ガン剤
MXPA97001860A (en) Intracellular supply of chemical agents, to a specific unit of cel
US6770631B1 (en) Non-identical genes and their application in improved molecular adjuvants
AU708304B2 (en) Targeting macromolecular prodrugs to T lymphocytes
US5621078A (en) Modified pseudomonas exotoxin PE40
WO2001027144A2 (fr) Mutants de la sous-unite b de la toxine ab5 aux caracteristiques de conjugaison chimique modifiees
WO1998051336A1 (fr) Administration ciblee vers des lymphocytes t
Riemen et al. Modified pseudomonas exotoxin PE 40
CA2372569A1 (fr) Composition de support d'immunogene de polypetide d'heterodimere et son procede d'utilisation

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic